Compared to Estimates, ResMed (RMD) Q1 Earnings: A Look at Key Metrics

ResMed (RMD) reported strong Q1 earnings, with revenue reaching $1.34 billion, a 9.1% year-over-year increase and a 0.94% beat over consensus estimates. Earnings per share (EPS) came in at $2.55, up from $2.20 in the prior year and surpassing the $2.49 estimate by 2.41%. The company demonstrated robust growth across most key segments, including devices and masks in both North American and international markets, largely exceeding analyst projections, although Residential Care Software revenue slightly missed estimates. Despite these positive results, RMD shares have declined 6.4% over the past month, underperforming the broader S&P 500, and currently hold a Zacks Rank #3 (Hold).

Analysis

ResMed (RMD) reported robust Q1 2025 financial results, with revenue reaching $1.34 billion, a 9.1% year-over-year increase, which surpassed the Zacks Consensus Estimate of $1.32 billion by 0.94%. Earnings per share (EPS) also demonstrated strength at $2.55, up from $2.20 in the prior year, exceeding the $2.49 consensus estimate by 2.41%. These headline figures indicate solid top and bottom-line growth for the company.

The company's performance was largely driven by strong segmental growth across both North American and international markets. U.S., Canada, and Latin America Devices revenue grew 7.5% to $413.4 million, and Masks and other revenue increased 11.9% to $361.3 million, both exceeding analyst projections. Similarly, the combined Europe, Asia, and other markets saw total revenue rise 9.5% to $394.7 million, with Devices revenue up 10.6%.

Despite these positive operational results, the Residential Care Software segment posted a slight revenue miss at $166.1 million against an estimated $170.38 million, though still growing 5.9% year-over-year. RMD shares have underperformed the broader market, returning -6.4% over the past month compared to the S&P 500's +3.6% gain. The stock currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the market in the near term.

Key Decisions for Investors

• Investors should closely monitor RMD's market reaction to these strong Q1 results, given its recent underperformance against the S&P 500 despite robust fundamental beats.
• Further analysis into the slight miss in Residential Care Software revenue is warranted to assess its impact on RMD's long-term growth trajectory and diversification efforts.
• Given the positive earnings report and the current Zacks Rank #3 (Hold), investors may consider maintaining existing positions while observing broader market and sector trends.